U.S. Markets closed

Tesaro, Inc. (TSRO)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
155.17+0.70 (+0.45%)
At close: 4:00PM EDT

155.17 0.00 (0.00%)
After hours: 4:42PM EDT

People also watch
CLVSKITEPBYIPTLAAGIO
Interactive chart
Previous Close154.47
Open154.28
Bid140.12 x 300
Ask162.00 x 100
Day's Range152.80 - 156.75
52 Week Range36.71 - 192.94
Volume705,566
Avg. Volume986,029
Market Cap8.36B
Beta2.35
PE Ratio (TTM)-18.21
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Conference Spotlights Drug Giant Donnybrooks In Cancer Treatments
    Investor's Business Daily5 days ago

    Conference Spotlights Drug Giant Donnybrooks In Cancer Treatments

    Preliminary data highlights breast, ovarian, lung and skin cancer data to presented during the American Society of Clinical Oncology meeting next month.

  • Capital Cube5 days ago

    TESARO, Inc. – Value Analysis (NASDAQ:TSRO) : May 18, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives TESARO, Inc. a score of 25. Our analysis is based on comparing TESARO, Inc. with the following peers – Clovis Oncology, Inc., ZIOPHARM Oncology, Inc., Amgen Inc., Cerulean Pharma, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Insys Therapeutics, Inc. and Pfizer Inc. (CLVS-US, ZIOP-US, AMGN-US, CERU-US, ... Read more (Read more...)

  • Did AstraZeneca Rival Just Launch A Potential Blockbuster Drug?
    Investor's Business Daily6 days ago

    Did AstraZeneca Rival Just Launch A Potential Blockbuster Drug?

    An analyst upgraded Clovis ahead of a key study for its ovarian cancer drug, which he said holds up against another from AstraZeneca.